Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE43.7500
- TODAY'S CHANGE (%)0.7500 (1.7442%)
- Bid / Lots42.4400/ 1
- Ask / Lots53.5000/ 1
- Open / Previous Close43.5800 / 43.0000
- Day Range
- 52 Week Range
- Volume252,216
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1184 | 43.58 |
| 09:41 ET | 100 | 43.59 |
| 09:43 ET | 661 | 43.68 |
| 09:45 ET | 200 | 43.45 |
| 09:50 ET | 650 | 43.5628 |
| 09:56 ET | 188 | 43.41 |
| 09:59 ET | 100 | 43.5 |
| 10:01 ET | 100 | 43.36 |
| 10:10 ET | 200 | 43.36 |
| 10:12 ET | 100 | 43.24 |
| 10:14 ET | 200 | 43.14 |
| 10:15 ET | 500 | 43.255 |
| 10:17 ET | 500 | 43.3 |
| 10:21 ET | 300 | 43.195 |
| 10:28 ET | 1400 | 42.87 |
| 10:30 ET | 100 | 42.98 |
| 10:32 ET | 817 | 42.915 |
| 10:33 ET | 1025 | 42.91 |
| 10:35 ET | 100 | 42.97 |
| 10:39 ET | 250 | 43.0571 |
| 10:44 ET | 200 | 43.07 |
| 10:46 ET | 1002 | 43.17 |
| 10:50 ET | 100 | 43.15 |
| 10:51 ET | 500 | 43.16 |
| 10:57 ET | 200 | 43.165 |
| 11:00 ET | 400 | 43.09 |
| 11:02 ET | 500 | 43.12 |
| 11:04 ET | 101 | 43.165 |
| 11:06 ET | 657 | 43.25 |
| 11:08 ET | 1400 | 43.4 |
| 11:09 ET | 200 | 43.335 |
| 11:13 ET | 200 | 43.33 |
| 11:22 ET | 300 | 43.29 |
| 11:26 ET | 5232 | 43.56 |
| 11:27 ET | 100 | 43.56 |
| 11:31 ET | 100 | 43.45 |
| 11:33 ET | 400 | 43.535 |
| 11:36 ET | 220 | 43.6 |
| 11:40 ET | 400 | 43.55 |
| 11:42 ET | 100 | 43.545 |
| 11:45 ET | 200 | 43.47 |
| 11:49 ET | 120 | 43.42 |
| 11:54 ET | 2100 | 43.445 |
| 11:58 ET | 1272 | 43.49 |
| 12:00 ET | 2300 | 43.49 |
| 12:02 ET | 100 | 43.5 |
| 12:07 ET | 200 | 43.53 |
| 12:09 ET | 296 | 43.5 |
| 12:12 ET | 200 | 43.5 |
| 12:14 ET | 100 | 43.54 |
| 12:16 ET | 400 | 43.51 |
| 12:18 ET | 100 | 43.52 |
| 12:21 ET | 533 | 43.52 |
| 12:25 ET | 100 | 43.555 |
| 12:34 ET | 200 | 43.5 |
| 12:38 ET | 470 | 43.5 |
| 12:39 ET | 100 | 43.52 |
| 12:41 ET | 2700 | 43.49 |
| 12:43 ET | 100 | 43.55 |
| 12:50 ET | 200 | 43.52 |
| 12:52 ET | 300 | 43.49 |
| 12:54 ET | 1200 | 43.485 |
| 12:56 ET | 2839 | 43.485 |
| 12:57 ET | 400 | 43.5 |
| 12:59 ET | 600 | 43.505 |
| 01:01 ET | 3482 | 43.51 |
| 01:03 ET | 2862 | 43.36 |
| 01:08 ET | 100 | 43.375 |
| 01:10 ET | 128 | 43.36 |
| 01:12 ET | 300 | 43.37 |
| 01:14 ET | 100 | 43.37 |
| 01:15 ET | 700 | 43.37 |
| 01:19 ET | 200 | 43.31 |
| 01:24 ET | 100 | 43.3 |
| 01:28 ET | 200 | 43.29 |
| 01:33 ET | 400 | 43.225 |
| 01:35 ET | 400 | 43.25 |
| 01:37 ET | 100 | 43.235 |
| 01:42 ET | 4736 | 43.46 |
| 01:44 ET | 100 | 43.4 |
| 01:46 ET | 200 | 43.37 |
| 01:48 ET | 2600 | 43.53 |
| 01:50 ET | 300 | 43.48 |
| 01:53 ET | 400 | 43.44 |
| 01:55 ET | 200 | 43.475 |
| 01:57 ET | 100 | 43.51 |
| 02:04 ET | 1078 | 43.59 |
| 02:08 ET | 1918 | 43.57 |
| 02:11 ET | 500 | 43.55 |
| 02:15 ET | 819 | 43.5 |
| 02:18 ET | 200 | 43.49 |
| 02:20 ET | 300 | 43.47 |
| 02:22 ET | 423 | 43.495 |
| 02:26 ET | 1200 | 43.43 |
| 02:27 ET | 400 | 43.4 |
| 02:29 ET | 3700 | 43.4 |
| 02:31 ET | 100 | 43.4 |
| 02:33 ET | 100 | 43.43 |
| 02:36 ET | 100 | 43.445 |
| 02:38 ET | 1900 | 43.43 |
| 02:40 ET | 600 | 43.42 |
| 02:42 ET | 1400 | 43.4 |
| 02:44 ET | 700 | 43.38 |
| 02:45 ET | 200 | 43.4 |
| 02:47 ET | 200 | 43.41 |
| 02:51 ET | 500 | 43.4 |
| 02:54 ET | 1200 | 43.4 |
| 02:56 ET | 400 | 43.47 |
| 02:58 ET | 100 | 43.465 |
| 03:00 ET | 4634 | 43.455 |
| 03:02 ET | 9613 | 43.46 |
| 03:03 ET | 2000 | 43.5 |
| 03:05 ET | 820 | 43.42 |
| 03:07 ET | 1500 | 43.49 |
| 03:09 ET | 200 | 43.51 |
| 03:12 ET | 1300 | 43.455 |
| 03:14 ET | 636 | 43.51 |
| 03:16 ET | 648 | 43.53 |
| 03:18 ET | 400 | 43.46 |
| 03:21 ET | 1206 | 43.52 |
| 03:23 ET | 500 | 43.535 |
| 03:25 ET | 100 | 43.525 |
| 03:27 ET | 2026 | 43.54 |
| 03:30 ET | 100 | 43.5 |
| 03:32 ET | 1010 | 43.525 |
| 03:36 ET | 1139 | 43.56 |
| 03:38 ET | 700 | 43.51 |
| 03:39 ET | 200 | 43.55 |
| 03:41 ET | 332 | 43.481 |
| 03:43 ET | 2900 | 43.53 |
| 03:45 ET | 200 | 43.55 |
| 03:48 ET | 2720 | 43.6 |
| 03:50 ET | 800 | 43.62 |
| 03:52 ET | 2998 | 43.61 |
| 03:54 ET | 700 | 43.615 |
| 03:56 ET | 14283 | 43.67 |
| 03:57 ET | 3095 | 43.64 |
| 03:59 ET | 11659 | 43.75 |
May 2, 2024
Apr 16, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 12, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones
7:13AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 10, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
9:57AM ET on Wednesday Apr 10, 2024 by Dow JonesXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.3B | -16.0x | --- |
SpringWorks Therapeutics Inc | 3.3B | -8.8x | --- |
Janux Therapeutics Inc | 3.3B | -48.3x | --- |
Summit Therapeutics Inc | 3.1B | -2.9x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 3.1B | -31.2x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -16.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
